VALIANT 2003

Methods	Multicentre, randomized, double‐blind, event‐driven, clinical trial. Median follow‐up: 24.7 months
Participants	Inclusion criteria: aged ≥ 18 years who had had acute myocardial infarction (0.5 to 10 days previously) that was complicated by clinical or radiological signs of heart failure or evidence of left ventricular systolic dysfunction Countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Russia, Slovakia, South Africa, Spain, Sweden, UK, US
Interventions	Monotherapy 1: valsartan 20 mg twice daily Monotherapy 2: captopril 6.25 mg 3 times daily Combination therapy: valsartan 20 mg twice daily + captopril 6.25 mg 3 times daily Doses were gradually increased with the goal of reaching valsartan 160 mg, captopril 50 mg or valsartan 80 mg + captopril 50 mg at 3 months. Investigators increased or decreased the doses of the study drugs at their discretion according to the participant's clinical status.
Outcomes	Primary: all‐cause mortality Secondary: cardiovascular death, acute coronary syndromes, cardiovascular morbidity, revascularization procedures, cardiovascular procedures, hospitalizations, adverse events
Notes	Participants were candidates to receive also beta‐blockers. Guidelines discourage the studied combination. We requested data of outcomes of interest for the subgroup of people with hypertension without previous treatment and without additional antihypertensive drugs but received no response.